MedTrace Logo

Pharmacogenomics Effects on High-Dose Methotrexate Clearance in Patients With Diffuse Large B-Cell Lymphoma

NCT06031194 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2026-01-06

No results posted yet for this study

Summary

This study evaluates pharmacogenomic effects on high-dose methotrexate clearance in patients with diffuse large B-cell lymphoma.

Conditions

  • Central Nervous System Lymphoma
  • Diffuse Large B-Cell Lymphoma

Interventions

OTHER

Non-Interventional Study

Non-interventional study

Sponsors & Collaborators

  • Ohio State University Comprehensive Cancer Center

    lead OTHER

Principal Investigators

  • Timothy Voorhees, MD · Ohio State University Comprehensive Cancer Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-10
Primary Completion
2025-11-05
Completion
2025-12-23

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06031194 on ClinicalTrials.gov